Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Davies, O.

Refine Results

Resource Type

Availability

Creation Date

Author

Show more

Language

Search results

  • RSS Feed
(1 - 20 of 21)

Pages

Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
Early Disease Activity or Clinical Response as Predictors of Long-Term Outcomes With Certolizumab Pegol in Axial Spondyloarthritis or Psoriatic Arthritis
FOUR-YEAR IMAGING OUTCOMES IN AXIAL SPONDYLOARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL, INCLUDING PATIENTS WITH ANKYLOSING SPONDYLITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS
CERTOLIZUMAB PEGOL FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS: 4-YEAR OUTCOMES FROM THE RAPID-AXSPA TRIAL
Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
Effect of certolizumab pegol on dermatologic outcomes over 96 weeks in patients with psoriatic arthritis
Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis
Structural Progression of the Spine Measured By X-Ray in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol over 96 Weeks, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
DISEASE ACTIVITY AND CLINICAL RESPONSE EARLY IN THE COURSE OF TREATMENT PREDICTS LONG-TERM OUTCOMES IN AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL
Effect of Certolizumab Pegol over 96 Weeks of Treatment on Inflammation of Spine and Sacroiliac Joints Measured By Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
OBSERVED INCIDENCE RATES OF UVEITIS FOLLOWING CERTOLIZUMAB PEGOL TREATMENT IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
DISEASE ACTIVITY AND CLINICAL RESPONSE EARLY IN THE COURSE OF TREATMENT PREDICT LONG-TERM OUTCOMES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL
DISEASE ACTIVITY AND CLINICAL RESPONSE EARLY IN THE COURSE OF TREATMENT PREDICT LONG-TERM OUTCOMES IN AXIAL SPONDYLOARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL
LOFAR: The LOw-Frequency ARray
TIMING AND MAGNITUDE OF INITIAL RESPONSE TO CERTOLIZUMAB PEGOL IN A BROAD POPULATION OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS PREDICTS LIKELIHOOD OF LDA AT WEEK 28
LOFAR: The LOw-Frequency ARray
CERTOLIZUMAB PEGOL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ALIGNED WITH NICE GUIDANCE FOR ANTI-TNF THERAPY: POST-HOC ANALYSES OF THE REALISTIC PHASE IIIB RANDOMIZED CONTROLLED STUDY

Pages